Free Trial
LON:ERGO

Ergomed (ERGO) Share Price, News & Analysis

Ergomed logo

About Ergomed Stock (LON:ERGO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
1,346
1,346
52-Week Range
N/A
Volume
280,999 shs
Average Volume
346,578 shs
Market Capitalization
£701.00 million
P/E Ratio
4,641.38
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ERGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter.

ERGO Stock News Headlines

Aktuelle Empfehlungen zur ERGOMED
Ergomedcro Unveils New Pune Office, Reinforcing Commitment to Global Growth
Which Gold Miner Trades at 30% of NAV? The One Buffett Wants
Some of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. With gold at record highs and Bridgewater now buying in, one analyst believes Buffett’s next move could hit by August 15th. He’s identified the gold miner that fits Buffett’s profile — plus four smaller plays with even more upside.
Icon PLC IJF
Green Mining Innovation: Neuer Chief Financing Officer
Green Mining Innovation: New Chief Financing Officer
See More Headlines

ERGO Stock Analysis - Frequently Asked Questions

Ergomed plc (LON:ERGO) issued its quarterly earnings data on Monday, September, 18th. The company reported $1.20 earnings per share (EPS) for the quarter. The company had revenue of $22.91 million for the quarter. Ergomed had a trailing twelve-month return on equity of 18.08% and a net margin of 9.87%.

Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), FuelCell Energy (FCEL), Frontier Developments (FDEV), Future (FUTR), Lloyds Banking Group (LLOY) and NIO (NIO).

Company Calendar

Last Earnings
9/18/2017
Today
7/12/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
LON:ERGO
CIK
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX 0.29
Trailing P/E Ratio
4,641.38
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£15 million
Net Margins
9.87%
Pretax Margin
N/A
Return on Equity
18.08%
Return on Assets
10.16%

Debt

Debt-to-Equity Ratio
3.32
Current Ratio
1.79
Quick Ratio
1.22

Sales & Book Value

Annual Sales
£152.09 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
54.67
Book Value
GBX 179 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
52,080,000
Free Float
N/A
Market Cap
£701.00 million
Optionable
Not Optionable
Beta
0.79
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (LON:ERGO) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners